Close
Help
Need Help?



Management of Pulmonary Arterial Hypertension with Sitaxentan Sodium

Submit a Paper



Publication Date: 13 Jan 2011

Type: Review

Journal: Clinical Medicine Insights: Therapeutics

Citation: Clinical Medicine Insights: Therapeutics 2011:3 31-38

doi: 10.4137/CMT.S5954

Abstract

Pulmonary arterial hypertension (PAH) is a chronic and progressive disease with a poor prognosis if left untreated. Pathophysiological alterations in this disease lead to vasoconstriction, endothelial and smooth muscle cell proliferation, and in situ thrombosis. Endothelin-1 (one of the most potent vasconstrictors known), has been shown to be increased in PAH, contributing, in part at least, to these abnormalities. Endothelin acts through the binding of two receptors, ETA and ETB. Sitaxentan is a selective ETA endothelin receptor antagonist that has been demonstrated, in several clinical trials, to improve exercise capacity, functional class and hemodynamics. Sitaxentan has a good safety profile, is well tolerated and has a low incidence of liver toxicity.


Downloads

PDF  (548.50 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)


Sharing

Our Service Promise

  • Prompt Processing (Less Than 3 Weeks)
  • Fair & Comprehensive Peer Review
  • Professional Author Service
  • Leading Editors in Chief
  • Extensive Indexing
  • High Readership & Impact
  • What Your Colleagues Say

Quick Links

Follow Us We make it easy to find new research papers.
Email AlertsRSS Feeds
FacebookGoogle+Twitter
PinterestTumblrYouTube

SUBJECT HUBS
Our Testimonials
Publishing in Air, Soil and Water and Water Research was the best experience I have had so far in an academic context.  The review process was fair, quick and efficient.  I congratulate the team at Libertas Academica for a very well managed journal.
Magnus Karlsson (IVL Swedish Environmental Research Institute, Stockholm, Sweden) What Your Colleagues Say